Corcept Therapeutics wins early FDA approval for Lifyorli in platinum-resistant ovarian cancer, boosting growth outlook.
Closed upsized initial public offering in February 2026, raising $381 million in gross proceedsCompleted enrollment of the TeLuRide-005 Phase 2 ...
MRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results